The TRPM4 A432T mutation causes a gain of function through slower deactivation driven by amino acid bulkiness, providing a mechanistic basis for its role in human cardiac conduction block.
Answers are grounded in this paper and cite their sources.
Informs variant interpretation in conduction disorders; extends channel kinetics insights but leaves open clinical translation.
A gain-of-function mutation in the Ca 2+ -activated transient receptor potential melastatin member 4 (TRPM4 A432T ) is linked to life-threatening cardiac conduction disturbance, but the underlying mechanism is unclear. For deeper insights, we used photolysis of caged Ca 2+ , quantitative Ca 2+ , and electrophysiological measurements. TRPM4 A432T 's 2-fold larger membrane current was associated with 50% decreased plasma membrane expression. Kinetic analysis unveiled 4-fold slower deactivation that was responsible for the augmented membrane current progressively rising during repetitive human cardiac action potentials. Rational mutagenesis of TRPM4 at position 432 revealed that the bulkiness of the amino acid was key to TRPM4 A432T 's aberrant gating. Charged amino acids rendered the channel non-functional. The slow deactivation caused by an amino acid substitution at position 432 from alanine to the bulkier threonine represents a key contributor to the gain of function in TRPM4 A432T . Thus, our results add a mechanism in the etiology of TRP channel-linked human cardiac channelopathies.
No takes yet. Share an insight, caveat, or question.
Xian et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: